Given this abundance of preclinical and clinical data, the recent availability of relatively potent progesterone antagonists with minimal antiglucocorticoid activity, such as telapristone acetate (TPA) and ulipristal acetate (UPA), has prompted renewed interest in selective PR modulators (SPRMs) for breast cancer prevention and therapy [11–17]. Here, PGR is linked to breast cancer.